Respiratory syncytial virus in adults: clinical features and innovative prophylaxis methods

O. Lebedeva Elena; L.A.  Davtian; I.K.  Kuznetsova; M.V.  Shutov; A. Rachina Svetlana

doi:10.36488/cmac.2025.3.275-288

Respiratory syncytial virus in adults: clinical features and innovative prophylaxis methods

Clinical Microbiology and Antimicrobial Chemotherapy. 2025; 27(3):275-288

Lebedeva E.O., Davtian L.A., Kuznetsova I.K., Shutov M.V., Rachina S.A.

10.36488/cmac.2025.3.275-288

respiratory tract diseases lower respiratory tract infections respiratory syncytial virus infections adults epidemiology

Section

Diseases and Pathogens

Type

Review

Publication

Clinical Microbiology and Antimicrobial Chemotherapy. 2025; 27(3):275-288

Abstract Authors Literature PDF Statistics

Abstract

This article analyzes epidemiological, pathogenetic, and clinical features of respiratory syncytial virus (RSV) infection in adults. It provides a review of current data on medical and healthcare burden of RSV in various regions worldwide, actual diagnostic and treatment methods for RSV-associated diseases, and approaches to non-specific and specific prevention, including an analysis of vaccine efficacy and safety. With the emergence of promising preventive measures, the importance of epidemiological monitoring of RSV incidence among adults in the Russian Federation is increasing to protect vulnerable populations and reduce the burden on healthcare system.

Elena O. Lebedeva

dr_lebedeva@bk.ru

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Davtian L.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Kuznetsova I.K.

Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia

Shutov M.V.

City Outpatient Clinic No. 64, Moscow, Russia

Svetlana A. Rachina

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

1. Morris J.A., Blount R.E., Savage R.E. Recovery of cytopathogenic agent from chimpanzees with goryza. Exp Biol Med. 1956;92:544-549. DOI: 10.3181/00379727-92-22538
2. Afonso C.L., Amarasinghe G.K., Bányai K., Bào Y., Basler C., Bavari S., et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol. 2016;161:2351-2360. DOI: 10.1007/s00705-016-2880-1
3. Borchers A.T., Chang C., Gershwin M.E. Respiratory syncytial virus – a comprehensive review. Clin Rev Allergy Immunol. 2013;45:331-379. DOI: 10.1007/s12016-013-8368-9
4. Sundaram M.E., Meece J.K., Sifakis F., Gasser R.A., Belongia E.A. Medically attended respiratory syncytial virus infections in adults aged >=50 years: clinical characteristics and outcomes. Clin Infect Dis. 2014;58:342-349. DOI: 10.1093/cid/cit767
5. Piedimonte G., Perez M.K. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35:519-530. DOI: 10.1542/pir.35-12-519
6. Nam H.H., Ison M.G. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021. DOI: 10.1136/bmj.l5021
7. Falsey A.R., Hennessey P.A., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749-1759. DOI: 10.1056/NEJMoa043951
8. Colosia A.D., Yang J., Hillson E., Mauskopf J., CopleyMerriman C., Shinde V., et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One. 2017;12:e0182321. DOI: 10.1371/journal.pone.0182321
9. Branche A.R., Saiman L., Walsh E.E., Falsey A.R., Sieling W., Greendyke W., et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis. 2022;74:1004-1011. DOI: 10.1093/cid/ciab595
10. Quarg C., Jörres R.A., Engelhardt S., Alter P., Budweiser P. Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022/2023 in a large German primary care centre. Eur J Med Res. 2023;28:568. DOI: 10.1186/s40001-023-01482-z
11. Savic M., Penders Y., Shi T., Branche A., Pirçon J.Y. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17:e13031. DOI: 10.1111/irv.13031
12. Obando-Pacheco P., Justicia-Grande A.J., Rivero-Calle I., Rodríguez-Tenreiro C., Sly P., Ramilo O., et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217:1356-1364. DOI: 10.1093/infdis/jiy056
13. Widmer K., Griffin M.R., Zhu Y., Williams J.V., Talbot H.K. Respiratory syncytial virus- and human metapneumovirusassociated emergency department and hospital burden in adults. Influenza Other Respir Viruses. 2014;8:347-352. DOI: 10.1111/irv.12234
14. Stensballe L.G., Devasundaram J.K., Simoes E.A.F. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003;22:S21-S32. DOI: 10.1097/01.inf.0000053882.70365.c9
15. Belongia E.A., King J.P., Kieke B.A., Pluta J., Al-Hilli A., Meece J.K., et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis. 2018;5:ofy316. DOI: 10.1093/ofid/ofy316
16. Al-Sharif H., El-Kafrawy S.A., Yousef J.M., Kumosani T.A., Kamal M.A., Khathlan N.A., et al. Dominance of the ON1 genotype of RSV-A and BA9 genotype of RSV-B in respiratory cases from Jeddah, Saudi Arabia. Genes. 2020;11:1323. DOI: 10.3390/genes11111323
17. Van Summeren J., Meijer A., Aspelund G., Casalegno G.S., Erna G., Hoang U., et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Eurosurveillance. 2021;26. DOI: 10.2807/1560-7917.ES.2021.26.29.2100639
18. Stamm P., Sagoschen I., Weise K., Plachter B., Münzel T., Gori T., et al. Influenza and RSV incidence during COVID-19 pandemic – an observational study from inhospital point-of-care testing. Med Microbiol Immunol (Berl). 2021;210:277-282. DOI: 10.1007/s00430-021-00720-7
19. Jia R., Lu L., Su L., Lin Z., Gao D., Lv H., et al. Resurgence of respiratory syncytial virus infection during COVID-19 pandemic among children in Shanghai, China. Front Microbiol. 2022;13:938372. DOI: 10.3389/fmicb.2022.938372
20. Joseph J., Achi S., Sheppard R., Ayinla R. Respiratory syncytial virus and SARS-CoV-2 co-infections during the COVID-19 pandemic: a case series of coexisting respiratory infections in a New York city public health care system. Chest. 2021;160:A382. DOI: 10.1016/j.chest.2021.07.383
21. Morales-Jadán D., Muslin C., Viteri-Dávila C., CastroRodríguez B., Vallejo-Janeta A.P., Henríqu A.R., et al. Coinfection of SARS-CoV-2 with other respiratory pathogens in outpatients from Ecuador. Front Public Health. 2023;11:1264632. DOI: 10.3389/fpubh.2023.1264632
22. Patel D.A., Marcum Z.A., Chansakul A., Toyip A., NerneyK., Panozzo C., et al. Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017-2019. Hum Vaccines Immunother. 2024;20:2364493. DOI: 10.1080/21645515.2024.2364493
23. Sominina A.A., Pisareva M.M., Grudinin M.P., Eropkin M.Yu., Konovalova N.I., Sukhovetskaya V.F., et al. Two years of experience in hospital surveillance for the severe influenza like illnesses in St. Petersburg: etiology, clinical characterization of diseases, antigenic and genetic properties of isolated influenza viruses. MIR J. 2015;2(1):44-55. DOI: 10.18527/2500-2236-2015-2-1-44-55
24. Weekly influenza and acute respiratory viral infection bulletin. Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation. Available at: www.influenza.spb.ru/surveillance/flubulletin/. Accessed September 9, 2025. Russian.
25. Krivitskaya V.Z. Respiratory syncytial virus infection. Pathogenesis peculiarities, prevention and treatment strategies. Curr Pediatr. 2013;12:35. DOI: 10.15690/vsp.v12i2.618
26. Kuhn J.H. Elevation of the paramyxoviral subfamily Pneumovirinae to family status as family Pneumoviridae in the order Mononegavirales; and renaming of one pneumoviral genus. Technical Report. June 2015. DOI: 10.13140/RG.2.1.2275.2081
27. McLellan J.S., Ray W.C., Peeples M.E. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83-104. DOI: 10.1007/978-3-642-38919-1_4
28. Krzyzaniak M.A., Zumstein M.T., Gerez J.A., Picotti P., Helenius A., et. al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9:e1003309. DOI: 10.1371/journal.ppat.1003309
29. Fuentes S., Tran K.C., Luthra P., Teng M.N., He B. Function of the respiratory syncytial virus small hydrophobic protein. J Virol. 2007;81:8361-8366. DOI: 10.1128/JVI.02717-06
30. Ruiz-Galiana J., Cantón R., De Lucas Ramos P., GarcíaBotella A., García-Lledó A., Hernández-Sampelayo T., et al. Respiratory syncytial virus: a new era. Rev Esp Quimioter. 2024;37:134-148. DOI: 10.37201/req/147.2023
31. Tomoya I., Naoto T., Yayoi A. Immunohistochemical detection of respiratory syncytial virus at autopsy. Pediatr Int. 2019;61(8):781-791. DOI: 10.1111/ped.13901
32. Durant L,R., Makris S., Voorburg C.M., Loebbermann J., Johansson C., Openshaw P.J.M., et al. Regulatory T Cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol. 2013;87:10946-10954. DOI: 10.1128/JVI.01295-13
33. Wang J., Kong L., Luo Q., Maj H. Dual effects of respiratory syncytial virus infections on airway inflammation by regulation of Th17/Treg responses in ovalbuminchallenged mice. Inflammation. 2014;37:1984-2005. DOI: 10.1007/s10753-014-9931-0
34. Lucey D.R., Clerici M., Shearer G.M. Type 1 and Type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9(4):532-562. DOI: 10.1128/CMR.9.4.532
35. Falsey A.R., Singh H.K., Walsh E.E. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol. 2006;78:1493-1497. DOI: 10.1002/jmv.20724
36. Mangodt T.C., Van Herck M.A., Nullens S., Ramet J., De Dooy J.J., Jorens P.J., et al. The role of Th17 and Treg responses in the pathogenesis of RSV infection. Pediatr Res. 2015;78:483-491. DOI: 10.1038/pr.2015.143
37. Hancock G.E., Tebbey P.W., Scheuer C.A., Pryharski K.S., Heers K.M., LaPierre N.A. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes. J Med Virol. 2003;70:301-308. DOI: 10.1002/jmv.10395
38. Bukreyev A., Yang L., Fricke J., Cheng L., Ward J.M., Murphy B.R., et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptorbearing leukocytes. J Virol. 2008;82:12191-12204. DOI: 10.1128/JVI.01604-08
39. Rossi G.A., Colin A.A. Respiratory syncytial virus – host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life. Pediatr Allergy Immunol. 2017;28:320-331. DOI: 10.1111/pai.12716
40. Self W.H., Williams D.J., Zhu Y., Ampofo K., Pavia A.T., Chappell J.D., et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2016;213:584-591. DOI: 10.1093/infdis/jiv323
41. Wald T.G., Miller B.A., Shult P., Drinka P., Langer L., Gravenstein S. et al. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc. 1995;43:170-174. DOI: 10.1111/j.1532-5415.1995.tb06384.x
42. Kenmoe S., Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis. 2024;37(2):129-136. DOI: 10.1097/QCO.0000000000001000
43. Walsh E.E., Peterson D.R., Falsey A.R. Is Clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis. 2007;195:1046-1051. DOI: 10.1086/511986
44. Sato R., Judy J., Yacisin K., Begier E., Sardana P., Agrawal N., et al. Immediate post-discharge care among US adults hospitalized with respiratory syncytial virus infection. BMC Pulm Med. 2024;24:486. DOI: 10.1186/s12890-024-03251-y
45. Mehta J., Walsh E.E., Mahadevia P.J., Falsey A.R. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD J Chronic Obstr Pulm Dis. 2013;10:293-299. DOI: 10.3109/15412555.2012.744741
46. DeMartino J.K., Lafeuille M.H., Emond B., Rossi C., Wang J., Liu S., et al. Respiratory syncytial virus-related complications and healthcare costs among a Medicareinsured population in the United States. Open Forum Infect Dis. 2023;10:ofad203. DOI: 10.1093/ofid/ofad203
47. Vega-Piris L., Carretero S.G., Mayordomo J.L., Zarzuelo M.B.R., Río V., García V.G., et al. Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 years. J Infect. 2024;89:106292. DOI: 10.1016/j.jinf.2024.106292
48. Ambrosch A., Luber D., Klawonn F., Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: risk factors, symptomatology and clinical course compared to influenza A / B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161:105399. DOI: 10.1016/j.jcv.2023.105399
49. Riccò M., Corrado S., Palmieri S., Marchesi F. Respiratory syncytial virus: a systematic review and meta-analysis of tomographic findings (2000-2022). Children. 2023;10:1169. DOI: 10.3390/children10071169
50. Mayer J., Lehners N., Egerer G., Kauczor H., Heußel C. CT-morphological characterization of respiratory syncytial virus (RSV) pneumonia in immune-compromised adults. RöFo. 2014;186:686-692. DOI: 10.1055/s-0033-1356353
51. Stefanidis K., Konstantelou E., Yusuf G.T., Oikonomou A., Tavernaraki K., Karakitsos D., et al. Radiological, epidemiological and clinical patterns of pulmonary viral infections. Eur J Radiol. 2021;136:109548. DOI: 10.1016/j.ejrad.2021.109548
52. Chulanov V.P., Gorelov A.V., Malyavin A.G. Clinical guidelines. Acute respiratory viral infections in adults, 2024. Available at: https://rnmot.org/video/repository/klinicheskie_rekomendacii_orvi_10102023_801a37eb.pdf. Accessed September 9, 2025. Russian.
53. Infectious Diseases. National Guidelines. Edited by Academician of the Russian Academy of Medical Sciences N.D. Yushchuk and Academician of the Russian Academy of Natural Sciences Yu.Ya. Vengerov. 2nd edition, revised and enlarged. Moscow: GEOTARMedia Publishing House, 2019. 1004 p. Russian.
54. Lin C.Y., Hwang D., Chiu N.C., Weng L.C., Liu H.F., Mu J.J., et al. Increased detection of viruses in children with respiratory tract infection using PCR. Int J Environ Res Public Health. 2020;17:564. DOI: 10.3390/ijerph17020564
55. Falsey A.R., Formica M.A., Walsh E.E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002;40:817-820. DOI: 10.1128/JCM.40.3.817-820.2002
56. Whiley D.M., Syrmis M.W., Mackay I.M., Sloots T.P. Detection of human respiratory syncytial virus in respiratory samples by LightCycler reverse transcriptase PCR. J Clin Microbiol. 2002;40:4418-4422. DOI: 10.1128/JCM.40.12.4418-4422.2002
57. Talbot H.K., Falsey A.R. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis. 2010;50:747-751. DOI: 10.1086/650486
58. Thuy T.T., Park H., Tuong H.T., Yu S.T., Choi D.U., Yeo S.J. Development of a rapid fluorescent immunochromatographic test to detect respiratory syncytial virus. Int J Mol Sci. 2018;19:3013. DOI: 10.3390/ijms19103013
59. Onwuchekwa C., Atwell J., Moreo L.M., Menon S., Machado B., Siapka M., et al. Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis. J Infect Dis. 2023;228:1516-1527. DOI: 10.1093/infdis/jiad185
60. Bierbaum S., Forster J., Berner R., Rücker G., Rohde G., Neumann-Haefelin D., et al. Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009/10. Arch Virol. 2014;159:669-676. DOI: 10.1007/s00705-013-1876-3
61. Onwuchekwa C., Moreo L.M., Menon S., Machado B., Curcio D., Kalina W., et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis. 2023;228:173-184. DOI: 10.1093/infdis/jiad012
62. Murphy C., Mak L., Cheng S.M.S., Kalina G.Y.Z., Chun A.M.C., Leung K.K.Y., et al. Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness. Diagn Microbiol Infect Dis. 2024;110:116421. DOI: 10.1016/j.diagmicrobio.2024.116421
63. Falsey A.R., Walsh E.E. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371-384. DOI: 10.1128/CMR.13.3.371
64. Walsh E.E., Falsey A.R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol. 2004;73:295-299. DOI: 10.1002/jmv.20090
65. Trang T.P., Whalen M., Hilts-Horeczko A., Doernberg S.B., Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018;20:e12844. DOI: 10.1111/tid.12844
66. Hall C.B., McBride J.T. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983;308(24):1443-1447. DOI: 10.1056/NEJM198306163082403
67. Ventre K., Randolph A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2010;2010(5):CD000181. DOI: 10.1002/14651858.CD000181.pub4
68. Chemaly R.F., Aitken S.L., Wolfe C.R., Jain R., Boeckh M.G. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18:634-636. DOI: 10.1111/tid.12551
69. DeVincenzo J., Tait D., Efthimiou J., Mori J., Kim Y.I., Thomas E., et al. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. Antimicrob Agents Chemother. 2020;64:e01884-19. DOI: 10.1128/AAC.01884-19
70. Mayo Clinic Press. Diseases & Conditions. Respiratory Syncytial Virus (RSV). 2023. Available at: www.mayoclinic.org/diseases-conditions/respiratory-syncytial-virus/symptoms-causes/syc-20353098. Accessed September 2025.
71. Wright M., Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol. 2011;46:324-347. DOI: 10.1002/ppul.21377
72. Corneli H.M., Holubkov R., Nelson K.A., Lillis K.A., Baskin M.N., Dean J.N., et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007;357(4):331-339. DOI: 10.1056/NEJMoa071255
73. Teeratakulpisarn J., Limwattananon C., Tanupattarachai S., Limwattananon S., Teeratakulpisarn S., Kosalaraksa P. Efficacy of dexamethasone injection for acute bronchiolitis in hospitalized children: a randomized, double-blind, placebo-controlled trial. Pediatr Pulmonol. 2007;42:433-439. DOI: 10.1002/ppul.20585
74. Karadag B., Ceran O., Guven G., Dursun E., Ipek I.O., Karakoc F., et al. Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis – a clinical trial. Respiration. 2008;76:283-287. DOI: 10.1159/000111817
75. Ermers M.J.J., Rovers M.M., Van Woensel J.B., Kimpen J.L.L., Bont L.J. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double-blind placebo-controlled trial. BMJ. 2009;338:b897-b897. DOI: 10.1136/bmj.b897
76. Chowdhury D., Howasi M.A., Khalil M., AlFrayh A.S., Chowdhury S., Ramia S. The role of bronchodilators in the management of bronchiolitis: a clinical trial. Ann Trop Paediatr. 1995;15:77-84. DOI: 10.1080/02724936.1995.11747752
77. Wang E.E., Milner R., Allen U., et. al. Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch Dis Child. 1992;67:289-293. DOI: 10.1136/adc.67.3.289
78. National Institute for Health and Care Excellence (NICE) guideline 2023. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management. Available at: www.nice.org.uk/guidance/ng237/resources/suspected-acute-respiratory-infectioninover-16s-assessment-at-first-presentation-and-initialmanagementpdf-66143901172165. Accessed September 2025.
79. Viguria N., Navascués A., Juanbeltz R., Echeverría A., Ezpeleta C., Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in highrisk children. Hum Vaccines Immunother. 2021;17:1867-1872. DOI: 10.1080/21645515.2020.1843336
80. Tenenbaum T., Liese J., Welte T., Rademacher J. Respiratory syncytial virus-associated respiratory diseases in children and adults. Dtsch Ärztebl Int. 2024;121(9):303-312. DOI: 10.3238/arztebl.m2024.0060
81. Order of the Moscow Department of Healthcare dated December 25, 2024, No. 4491-r, «On measures aimed at the all-season prevention of respiratory syncytial virus infection in children in the city of Moscow, financed from the Moscow city budget.» 2024. Available at: www.mos.ru/dzdrav/documents/department-acts/view/315622220/. Accessed September 9, 2025. Russian.
82. Alfano F., Bigoni T., Caggiano F.P., Papi A. Respiratory syncytial virus infection in older adults: an update. Drugs Aging. 2024;41:487-505. DOI: 10.1007/s40266-024-01118-9
83. Walsh E.E., Pérez Marc G., Zareba A.M., Falsey A.R., Jiang Q., Patton M. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388:1465-1477. DOI: 10.1056/NEJMoa2213836
84. Papi A., Ison M.G., Langley J.M., Lee D.G., LerouxRoels I., Martinon-Torres F., et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388:595-608. DOI: 10.1056/NEJMoa2209604
85. Wilson E., Goswami J., Baqui A.H., Doreski P.A., Perez-Marc G., Zaman K., et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389:2233-2344. DOI: 10.1056/NEJMoa2307079
86. Kaslow D.C. Approval letter: Arexvy. Silver Spring. MD: US Department of Health and Human Services, Food and Drug Administration 2023. Available at: www.fda.gov/media/167806/download. Accessed September 2025.
87. Kaslow D.C. Approval letter: Abrysvo. Silver Spring. MD: US Department of Health and Human Services, Food and Drug Administration 2023. Available at: www.fda.gov/media/168890/download. Accessed September 2025.
88. Walsh E.E. RENOIR Trial – RSVpreF vaccine efficacy over two seasons. N Engl J Med. 2024;391:1459-1460. DOI: 10.1056/NEJMc2311560
89. Tartof S.Y., Aliabadi N., Goodwin G., Slezak J., Hong V., Ackerson B., et al. Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease. JAMA Netw Open. 2024;7:e2450832. DOI: 10.1001/jamanetworkopen.2024.50832
90. Payne A.B., Watts J.A., Mitchell P.K., Dascomb K., Irving S.A., Klein N.P., et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. The Lancet. 2024;404:1547-1559. DOI: 10.1016/S0140-6736(24)01738-0
91. Vaccine Scheduler, RSV: Recommended Vaccinations. Available at: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=53&SelectedCountryIdByDisease=-1. Accessed September 2025.
92. FDA approves first vaccine for pregnant individuals to prevent RSV in infants. United States: Food and Drug Administration; Available at: www.fda.gov/newsevents/press-announcements/fda-approves-first-vaccinepregnantindividuals-prevent-rsv-infants. Accessed September 2025.
93. Simões E.A.F., Center K.J., Tita A.T.N., Swanson K.A., Radley D., Houghton J., et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386:1615-1626. DOI: 10.1056/NEJMoa2106062
94. Walsh E.E., Falsey A.R. Scott D.A. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. 2022;225:1357-1366. DOI: 10.1093/infdis/jiab612
95. Pfizer’s ABRYSVO® receives positive CHMP opinion for adults aged 18 to 59. Available at: www.pfizer.com/news/announcements/pfizers-abrysvor-receives-positivechmpopinion-adults-aged-18-59. Accessed September 2025.
96. Leroux-Roels, I., Davis, M.G., Steenackers, K. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227:761-772. DOI: 10.1093/infdis/jiac327
97. Ison M.G., Papi A., Athan E. (AReSVi-006 Study Group). Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024;78(6):1732-1744. DOI: 10.1093/cid/ciae010
98. Hong-Nguyen Y.K., Toerner J., Lee L., Allende M.C., Kaslow D.C. Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization. NPJ Vaccines. 2024;9:210. DOI: 10.1038/s41541-024-01002-y
99. ModernaTX, Inc. A study of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in adults ≥50 years of age (RSVictory). Available at: https://clinicaltrials.gov/study/NCT05330975. Accessed September 2025.
100. Food and Drug Administration. Approval letter: mRESVIA. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. 2024. Available at: www.fda.gov/media/179015/download. Accessed September 2025.
101. European Medicines Agency. European Public Assessment Report (EPAR)-mRESVIA. Available at: www.ema.europa.eu/en/documents/product-information/mresvia-eparproductinformation_en.pdf. Accessed September 2025.
102. Goswami J., Cardona J.F., Hsu D.C., Simorellis A.K., Wilson L., Dhar R., et al. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect Dis, 2024:S1473309924005899. DOI: 10.1016/S1473-3099(24)00589-9
103. Food and Drug Administration (FDA). FDA Requires Guillain-Barré Syndrome (GBS) Warning in the prescribing information for RSV vaccines Abrysvo and Arexvy. 2025. Available at: www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-guillain-barresyndromegbs-warning-prescribing-information-rsvvaccinesabrysvo-and. Accessed September 2025.
104. On the interim results of a clinical trial of a vaccine against respiratory syncytial virus infection. Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation. Available at: www.influenza.spb.ru/news/id806/. Accessed September 9, 2025. Russian.
105. Zubkova T., Research Institute of Influenza, Russia (Responsible Party). Evaluation of RSV/Flu-01E vaccine for the prevention of RSV infection in volunteers aged 18 to 59 years and over 60 years n.d. Available at: https://clinicaltrials.gov/study/NCT05970744. Accessed September 2025.
106. Fuchs J., Hübner J., Schmidt A., Irrgang P., Maier C., Viera Antao A., et al. Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus. NPJ Vaccines. 2024;9:205. DOI: 10.1038/s41541-024-01001-z
107. Centers for Disease Control and Prevention (CDC). Infection prevention and control recommendations for healthcare settings. 2020. Available at: www.cdc.gov/infection-control. Accessed September 2025.
108. Messina A., Germano C., Avellis V., Tavella E., Dodaro V., Massaro A., et al. New strategies for the prevention of respiratory syncytial virus (RSV). Early Hum Dev. 2022;174:105666. DOI: 10.1016/j.earlhumdev.2022.105666
109. Wong S.C., Lam G.M., AuYeung C.Y., Chan V.W.M., Wong N.L.D., So S.Y.K., et al. Absence of nosocomial influenza and respiratory syncytial virus infection in the coronavirus disease 2019 (COVID-19) era: implication of universal masking in hospitals. Infect Control Hosp Epidemiol. 2021;42:218-221. DOI: 10.1017/ice.2020.425
110. Sung A.D., Sung J.A.M., Thomas S., Hyslop T., Gasparetto C., Long G., et al. Universal mask usage for reduction of respiratory viral infections after stem cell transplant: a prospective trial. Clin Infect Dis. 2016;63:999-1006. DOI: 10.1093/cid/ciw451
111. La E.M., Bunniran S., Garbinsky D., Reynolds M., Schwab Ph., Poston S., et al. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccines Immunother. 2024;20:2303796. DOI: 10.1080/21645515.2024.2303796

Views

0 Abstract

0 PDF

0 Crossref citations

Respiratory syncytial virus in adults: clinical features and innovative prophylaxis methods

Abstract

Views

Shared

Cited by Crossref